Literature DB >> 9052419

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

D Papamichael1, C J Gallagher, R T Oliver, P W Johnson, J Waxman.   

Abstract

Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9052419      PMCID： PMC2063294          DOI： 10.1038/bjc.1997.106

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  7 in total

Review 1.  The emerging role of paclitaxel in breast cancer therapy.

Authors:  A D Seidman
Journal:  Clin Cancer Res       Date:  1995-03       Impact factor: 12.531

2.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

Authors:  W P McGuire; E K Rowinsky; N B Rosenshein; F C Grumbine; D S Ettinger; D K Armstrong; R C Donehower
Journal:  Ann Intern Med       Date:  1989-08-15       Impact factor: 25.391

3.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

Authors:  W K Murphy; F V Fossella; R J Winn; D M Shin; H E Hynes; H M Gross; E Davilla; J Leimert; H Dhingra; M N Raber
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

Review 4.  Chemotherapy for urothelial tract malignancies: breaking the deadlock.

Authors:  H I Scher; L Norton
Journal:  Semin Surg Oncol       Date:  1992 Sep-Oct

5.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

6.  Taxol and taxotere in bladder cancer: in vitro activity and urine stability.

Authors:  C Rangel; H Niell; A Miller; C Cox
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

Authors:  B J Roth; R Dreicer; L H Einhorn; D Neuberg; D H Johnson; J L Smith; G R Hudes; S M Schultz; P J Loehrer
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544
  7 in total
  26 in total

1.  Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.

Authors:  Pedro C Barata; Dhrmesh Gopalakrishnan; Vadim S Koshkin; Prateek Mendiratta; Matt Karafa; Kimberly Allman; Allison Martin; Jennifer Beach; Pam Profusek; Allison Tyler; Laura Wood; Moshe Ornstein; Timothy Gilligan; Brian I Rini; Jorge A Garcia; Petros Grivas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

2.  Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.

Authors:  Jae-Lyun Lee; Jin-Hee Ahn; Se Hoon Park; Ho Young Lim; Jung Hye Kwon; Shin Ahn; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  Invest New Drugs       Date:  2011-10-20       Impact factor: 3.850

3.  Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Authors:  Mark Warren; Michael Kolinsky; Christina M Canil; Piotr Czaykowski; Srikala S Sridhar; Peter C Black; Christopher M Booth; Wassim Kassouf; Libni Eapen; Som D Mukherjee; Normand Blais; Bernhard J Eigl; Eric Winquist; Naveen S Basappa; Scott A North
Journal:  Can Urol Assoc J       Date:  2019-04-26       Impact factor: 1.862

Review 4.  Improving Systemic Chemotherapy for Bladder Cancer.

Authors:  Tracy L Rose; Matthew I Milowsky
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

5.  The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.

Authors:  Nobuki Furubayashi; Takahito Negishi; Takuya Yamashita; Shuhei Kusano; Kenichi Taguchi; Mototsugu Shimokawa; Motonobu Nakamura
Journal:  Mol Clin Oncol       Date:  2017-10-13

Review 6.  Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

Authors:  Jorge García; Lucia Santomé; Urbano Anido; Ovidio Fernández-Calvo; Javier Afonso-Afonso; Martín Lázaro; Ana Medina; Sergio Vázquez Estévez
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

7.  Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer.

Authors:  J Dunst; C Weigel; H Heynemann; A Becker
Journal:  Strahlenther Onkol       Date:  1999-10       Impact factor: 3.621

Review 8.  State-of-the-art management of metastatic disease at initial presentation or recurrence.

Authors:  Fabio Calabrò; Cora N Sternberg
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

9.  Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.

Authors:  Kunimitsu Kanai; Eiji Kikuchi; Takashi Ohigashi; Akira Miyajima; Ken Nakagawa; Jun Nakashima; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 10.  Management of bladder cancer: current and emerging strategies.

Authors:  Neeraj Agarwal; Maha Hussain
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.